47 completed, 6 unknown, 3 recruiting, 2 terminated. 60 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 60 | Completed 47, Unknown 6, Recruiting 3, Terminated 2, Active not recruiting 1, Enrolling by invitation 1 |
| Phase 2 | 6 | Completed 4, Active not recruiting 1, Terminated 1 |
Follow Crystal Arthropathies: new trials by email Literature Review of Crystal Arthropathies trials Research Report on Crystal Arthropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IN026 in Participants With Refractory Gout IN026 Injection - Refractory Gout | Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 16 | 2026-06-12 | 2026-07-31 |
| Drug-Drug Interaction Study of ABP-671 in Gout Patients ABP-671 plus allopurinol - Gout Chronic, Gout | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 22 | 2026-01-23 | 2026-11-02 |
| Stem Cell Treatment for Regeneration of the Rotator Cuff (Lipo-Cuff Study) Stem-cell treatment, Standard care - Rotator Cuff Tears, Rotator Cuff Injuries | Phase 1 | Enrolling by invitation | University of Southern Denmark | 30 | 2024-09-03 | 2026-10-08 |
| A Bioequivalence Study of Two Different Dosage Form of Genakumab Genakumab Injection (T, Solution for injection), Genakumab for Injection (R, Powder for solution for injection) - Gouty Arthritis (GA) | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 178 | 2024-06-24 | 2025-02-11 |
| PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function SAP-001 - Gout, Hyperuricemia | Phase 1 / Phase 2 | Active not recruiting | Shanton Pharma Pte. Ltd. | 32 | 2024-04-24 | 2024-12-11 |
| Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout Rituximab - Tophaceous Gout | Phase 1 | Completed | University of California, Los Angeles | 2 | 2024-04-10 | 2025-11-20 |
| A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) dose-5 group, dose-1 group, dose-2 group - Gout Arthritis | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 30 | 2024-03-05 | 2024-03-22 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers ABP-745, Placebo - Gout, Acute Gout Flare | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 90 | 2024-01-23 | 2025-08-17 |
| PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo - Gout and Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2024-01-04 | 2024-03-06 |
| Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia Pegylated Recombinant Candida Utilis Uricase for Injection - Gout, Hyperuricemia | Phase 1 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 60 | 2023-11-20 | 2025-05-28 |
| Effect of Tigulixostat on the Pharmacokinetics of Theophylline Tigulixostat, Theophylline - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 24 | 2023-10-31 | 2024-01-03 |
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| The MAD Study of SSGJ-613 in Healthy Subjects SSGJ-613, Placebo - Arthritis, Gouty | Phase 1 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 36 | 2023-08-10 | 2023-08-01 |
| SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects SAP-001, Placebo - Gout, Hyperuricemia | Phase 1 | Completed | Shanton Pharma Co., Ltd. | 70 | 2023-05-29 | 2024-11-12 |
| A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels PRX-115, Placebo - Gout | Phase 1 | Completed | Protalix | 64 | 2023-03-23 | 2025-02-11 |
| A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. SIBP-R002, Methotrexate - Gout | Phase 1 | Recruiting | Shanghai Institute Of Biological Products | 36 | 2023-03-03 | 2026-01-08 |
| Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout Phase 1b: HZBio1 3mg, Phase 1b: HZBio1 6mg, Phase 1b: HZBio1 12mg - Gout | Phase 1 / Phase 2 | Completed | Hangzhou Grand Biologic Pharmaceutical, Inc. | 90 | 2022-06-23 | 2026-08-07 |
| A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout ALN-XDH, Placebo - Gout | Phase 1 / Phase 2 | Terminated | Alnylam Pharmaceuticals | 44 | 2022-02-25 | 2024-03-29 |
| Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal, Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state - Hyperuricemia, Gout | Phase 1 | Completed | Allena Pharmaceuticals | 12 | 2022-01-11 | 2023-01-23 |
| A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing HEC93077, Placebo - Gout | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 126 | 2021-11-22 | 2026-05-01 |
Showing 20 of 60. Sign in to see all of them.
Gout (56) · Hyperuricemia (28) · Arthritis, Gouty (3) · Chronic Pain (1) · Coronary Artery Disease (1) · Heartburn (1) · Metabolic Diseases (1) · Rheumatic Diseases (1) · Rotator Cuff Injuries (1) · Rotator Cuff Tear Arthropathy (1)
Arthritis (60) · Joint Diseases (60) · Musculoskeletal Diseases (60) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (59) · Genetic Diseases, Inborn (59) · Metabolism, Inborn Errors (59) · Nutritional and Metabolic Diseases (59) · Purine-Pyrimidine Metabolism, Inborn Errors (59) · Metabolic Diseases (58) · Rheumatic Diseases (58) · Pathological Conditions, Signs and Symptoms (30) · Pathologic Processes (28) · Gout (3) · Signs and Symptoms (2)
ruzinurad (6) · verinurad (6) · Allopurinol (4) · Injections (3) · lesinurad (3) · Colchicine (2) · Febuxostat (2) · Naproxen (2) · Anti-Inflammatory Agents, Non-Steroidal (1) · Benzbromarone (1) · Indomethacin (1) · Methotrexate (1) · Midazolam (1) · Powders (1) · Rituximab (1)
Ardea Biosciences, Inc. (8) · LG Chem (6) · Atom Therapeutics Co., Ltd (5) · Jiangsu HengRui Medicine Co., Ltd. (4) · Allena Pharmaceuticals (3) · Shenyang Sunshine Pharmaceutical Co., LTD. (3) · AstraZeneca (2) · Atridia Pty Ltd. (2) · EnzymeRx (2) · InventisBio Co., Ltd (2) · Selecta Biosciences, Inc. (2) · Shanton Pharma Co., Ltd. (2) · Alnylam Pharmaceuticals (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Evopoint Biosciences Inc. (1)
United States (31) · China (17) · Australia (3) · South Korea (2) · United Kingdom (2) · Brazil (1) · Denmark (1) · Japan (1) · New Zealand (1)
J. Hall, MD (4) · Anthony S Fiorino, MD, PhD (2) · S Bradley, MD (2) · Alan Kivitz, MD (1) · Christine Tosone (1) · Christine Tosone, MS (1) · Christine Tosone, MS, RAC (1) · Danielle Armas, M.D. (1) · Danielle Armas, MD (1) · Huan Zhou, Master (1) · Hugh Coleman, MD (1) · Ji-Young Park, M.D., Ph.D. (1) · Jianzhong Shentu, Doctor (1) · John FitzGerald, MD (1) · John M Hill, MD (1)
PMID 35022448, PMID 29868853, PMID 29949102, PMID 32951150, PMID 39427182, PMID 39530130, PMID 41388232